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Abstract Formyl peptide receptor 1 (FPR1) activity in
U87 glioblastoma (GBM) cells contributes to tumor cell
motility. The present study aimed to evaluate the FPR1
expression in human GBM, the possibility to elicit agonist
induced FPR1 activation of GBM cells and inhibit this
activation with chemotaxis inhibitory protein of Staphylo-
coccus aureus (CHIPS). Immunohistochemistry was used
to assess FPR1 expression in GBM patient samples, which
was present in all 178 samples. Also FPR1 mRNA levels
measured with quantitative PCR, could be detected in all
25 GBM patient samples tested. Activation of FPR1 in U87
cells, as measured by human mitochondrial-derived ago-
nists, increased calcium mobilization, AKT and ERK1/2
phosphorylation, and ligand-induced migration. Inhibition
of all responses could be achieved with CHIPS. Eight early
passage human Groningen Glioma (GG) cell lines, isolated
from primary GBM tissue were screened for the presence
of FPR1. FPR1 mRNA and protein expression as well as
receptor activation could not be detected in any of these
early passage GG cell lines. However FPR1 was present in
ex vivo tumors formed by the same GG cell lines after
being implanted in mouse brains. FPR1 is highly expressed
in human GBM specimens, it can be activated by human
mitochondrial-derived agonists in U87 and inhibited with
CHIPS. FPR1 cannot be detected in early passage GG cell
lines in vitro, however when engrafted in the mouse brain
these cells show FPR1 expression. These results suggest a
role of the brain microenvironment in FPR1 expression in
GBM.
Keywords FPR1  GBM  Mitochondrial peptides  GBM
cells
Introduction
Glioblastoma (GBM) accounts for circa 65 % of malignant
gliomas [1, 2]. Treatment options post surgical resection,
consist of radiotherapy with concomitant temozolomide
resulting in median survival of 12–15 months [3, 4]. The
highly infiltrative nature of GBM and its seemingly pre-
ordained recurrence contribute to the necessity of devel-
oping new treatment options. Inhibition of tumor cell
migration could be a therapeutic strategy. In this respect
the formyl peptide receptor 1 (FPR1) might be of interest.
FPR1 is a G-protein coupled receptor (GPCR) originally
identified by its capability to mediate phagocytic leukocyte
migration. Agonists for FPR1 are formylated peptides such
as the bacterial derived fMLF, and mitochondrial derived
fMLKLIV and fMMYALF [5]. Additionally supernatant
from necrotic tumor cells may activate FPR1 on U87 cells
[6]. Formylated peptide induced activation of phagocytic
leukocytes can be inhibited by Chemotaxis Inhibitory
Protein of Staphylococcus aureus (CHIPS). CHIPS is an
immune evasion protein secreted by S. aureus [7] and a
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selective inhibitor of FPR1 which potently abrogates the
migration of neutrophils and monocytes towards the site of
infection [8].
Stimulation of human U87 GBM cells with fMLF elicits
the upregulation of hypoxia inducible factor 1-alpha
(HIF1a) [6] and of vascular endothelial growth factor
(VEGF) [6, 9]. Moreover FPR1 receptor activation pro-
duces downstream protein phosphorylation of ERK1/2 and
AKT, which are early signalling events of cell proliferation
and migration [10, 11]. In addition these effects can be
inhibited by CHIPS [9]. Furthermore, CHIPS treatment
showed modest but improved survival of mice with sub-
cutaneously implanted U87 xenografts [9].
In this study we investigated FPR1 expression in human
GBM. We analyzed if human mitochondrial peptides could
lead to activated FPR1 mediated responses by U87 cells
and whether CHIPS could inhibit these responses. In ad-
dition early passage Groningen Glioma (GG) cells were
screened for functional FPR1 expression and presence of
FPR1 mRNA. Finally we compared the presence of FPR1




The human GBM cell line U87 was purchased from the
ATCC (HTB-14) and cultured as previously described [9].
GG lines; GG1, GG6, GG7, GG9, GG12, GG13, GG14 and
GG16, isolated from eight primary GBM specimens, were
kept at low passage numbers and cultured as previously
described [12].
Tissue collection
A total of 178 GBM patient specimens were collected. Of
these, 141 samples were formalin fixed paraffin embedded
(FFPE)(4 cores per tumor) on tissue micro arrays (TMA). In
addition 37 frozen specimens with good quality material
were used for cryostaining. For 25 specimens sufficient ad-
ditional tissue was available for quantitative (q)PCR analy-
sis. The paired diagnostic paraffin tumor tissues from which
the GG cell lines were isolated was used for comparative
staining. Additional control sections of 3 pneumonia and 1
healthy brain tissue were included. All patient samples were
retrieved from the tissue bank at the Department of Pathol-
ogy at the UMCG and collected between 2005–2012 (FFPE
samples) and 1998–2007 (cryosections). Tumor tissues were
numerically tagged based on a national coding system. Ac-
cording to Dutch law, no further Institutional review and
board approval was required.
From NOD scid gamma mice (NOD.Cg-Prkdcscid -
Il2rgtm1Wjl/SzJ)/NSG mice), orthotopically implanted with
GG12, GG13, GG14 and GG16 FFPE coronal sections
were obtained as previously described [12].
Ca21 mobilization assay
GPCR activation is measurable by calcium release [13] upon
ligand induced receptor activation. Calcium-mobilization by
10-6–10-8 M fMLKLIV and fMMYALF in U87 cells and
10-5 M fMLF in GG cell lines, was performed as previously
described [9]. For inhibition experiments, cells pre-incu-
bated with 0.01, 0.1, 1 or 10 lg/mL CHIPS for 15 min at
room temperature (RT) were stimulated with 10-7 M
fMLKLIV and or 10-6 M fMMYALF. Stimulation/
inhibition was calculated using the following formula:
[(MFsample–bgFsample)/(MFmax–bgFmax)] 9 100 % in which
MFsample = mean fluorescence sample, bgFsample = back-
ground fluorescence sample, MF = mean fluorescence with
stimulation and bgF = background fluorescence without
stimulation [14].
Quantitative PCR
Total RNA extraction was obtained from 25 GBM samples,
and GG1, GG6, GG7, GG9, GG12, GG13, GG14, GG16
cell lines. U87 served as a positive control and a no tem-
plate control (water) served as negative control. RNA was
extracted following RNeasy mini kit guidelines (Qiagen,
Venlo, The Netherlands) for the GBM samples or with
TRIzol-reagent (Ambion Life Technologies, Blijswijk,
The Netherlands) by adding 1 mL of TRIzol to a 25 cm2
(U87 and GG7) or 75 cm2 culture flask (all other GG cell
lines). TRIzol-treated samples were incubated for 10 min,
mixed with 200 lL chloroform/mL TRIzol and cen-
trifuged each time at 4 C and 21,3009g for 5 min. Sam-
ples were incubated with 500 lL isopropyl alcohol per
1 mL TRIzol for 10 min and centrifuged. RNA pellet was
washed with 75 % ethanol, centrifuged, air-dried and
quantified using a NanoDrop ND-00-spectrophotometer
(Thermo Scientific, Breda, The Netherlands). Following
Ambion guidelines total RNA was treated with TURBO
DNA-free kit; the quality and integrity were detected by
ethidium bromide (Invitrogen) staining on 1.2 % agarose
gel. Synthesis of cDNA was performed following iSCRIPT
guidelines (Bio-Rad Laboratories, Veenendaal, The
Netherlands) and quality was checked with a ladder PCR
using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as a loading control. The qPCR was performed
using TaqMan Universal Master Mix (Life Technologies)
and measured on ABI PRISM 7900HT real-time sequence
detection system (Applied Biosystems, Forster City, CA) in
a 384-well reaction plate. Primers from Life Technologies
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included FPR1 (HS04235429_S1) and GAPDH
(Hs02758991_g1). Raw data was extracted with SDS
software 2.3 (Applied Biosystems) and averages of
threshold cycles (CT) were used for calculations of relative
expression with the 2-Dct method. GAPDH CT served as
background value with cutoff set at CT values of 40 cycles.
Immunohistochemistry and staining evaluation
FFPE (4 lm) slides were deparaffinized and rehydrated.
Endogenous peroxidase was blocked with 0.33 % H2O2,
antigen retrieval was performed with TrisHCl (pH 9)/mi-
crowave. Primary FPR1 antibody (ab#150533, Abcam,
Cambridge, UK) antibody diluted in 1 % bovine serum
albumin (BSA)/phosphate buffered saline, 2.7 mM KCl,
1.8 mM KH2PO4, 137 mM NaCl, 10.1 mM Na2HPO4,
pH = 7.4 (PBS) was incubated at 4 C overnight. Se-
condary, tertiary antibodies (Table 1) and 3,3-di-
aminobenzidine (DAB) system were applied and slides
were dehydrated and coverslipped.
Snap frozen tissue (4 lm) sections were mounted on
Starfrost adhesive slides, dried for 20 min, acetone-fixed
for 10 min and incubated with primary FPR1 antibody
(ab#101659, Abcam) in 1 % BSA/PBS at RT for 1 h.
Subsequently, secondary and tertiary antibodies were ap-
plied, followed by 3-amino-9-ethylcarbazole (AEC) de-
tection. Slides were mounted with Kaiser’s glycerol-gelatin
(Millipore Corporation, Amsterdam, the Netherlands).
Omission of primary antibody or an appropriate prepara-
tion of IgG served as a negative control. Normal brain and
pneumonia tissue samples served as controls for antibody
specificity. In pneumonia tissue a high FPR1 positivity on
infiltrated neutrophils and bronco-alveolar epithelial cell is
expected [15, 16]. In the cerebral cortex a moderate neuron
positivity is expected [14].
Immunohistochemical evaluation of TMA was assessed
by double blind scoring of slide scans acquired with Aperio
ImageScope. Semi-quantitative evaluation was performed
by attributing 0 (negative) to 3 (positive) scores. Averages
of the 4 cores from both observers representing each pa-
tient sample were calculated.
Quantitative evaluation of frozen sections was per-
formed using Olympus WH10-H/22 grid by calculating the
percentage of all positive cells counted within the grid in
4 high power fields (400x) randomly selected throughout
each tumor slide.
Western blot
For Western blot analysis U87 cells (1 9 106) were seed-
ed, starved for 24 h and pre-incubated with culture medium
or 10 lg/mL CHIPS for 20 min at RT. Subsequently, U87
cells were treated for 5, 15, 30 min with culture medium
only or containing, 10-6 M fMMYALF or fMLKLIV.
Cells were washed twice with 1.5 mL ice cold PBS, lysed
with 40 lL mammalian protein extraction reagent
(MPER)(Thermo Scientific) including 1:100 protease
(Thermo Scientific), 1:100 phosphatase (Thermo Scien-
tific) inhibitors and incubated for 1 h on ice. Im-
munoblotting for phosphorylated Akt(ser473) and ERK1/2
was performed as previously described [9].
Migration
Eight lm pore-Corning Transwell polycarbonate mem-
brane cell culture inserts (Sigma-Aldrich, Zwijndrecht, The
Netherlands) were coated and blocked as previously de-
scribed [9]. Lower wells were loaded with 300 lL of 10-6
M fMLF, fMMYALF or fMLKLIV in Dulbecco’s modified
Eagle’s medium high glucose (DMEM-H)/0.5 % BSA.
Before treatment U87 cells were serum starved for 2 days
and subsequent steps were performed in serum-free
DMEM-H medium. Next, 6 9 105 U87 cells/mL were in-
cubated for 15 min with control medium or medium with
10 lg/mL CHIPS. Then, 150 lL containing 105 U87 cells
were loaded on top of transwell inserts in triplicates. U87
cells migrated towards medium containing 10-6 M fMLF,
fMMYALF or fMLKLIV for 5 h at 37 C in 5 % CO2
humidified atmosphere. Transwell inserts were cleaned;
cells were fixed and counted as previously described [9].
Immunofluorescence
Paraffin sections of GBM patient specimens (4 lm) were
deparaffinized, hydrated in demi water, washed with PBS,
blocked with PBS/1 % BSA and stained with anti-FPR1
Table 1 List of antibodies used
Antibody Source Antigen retrieval Type Dilutions and conditions
FPR1 Abcam ab150533 Tris–HCl, 15 min MW Rabbit Polyclonal 1:250; O/N 4 C
Abcam ab101659 None Rabbit Polyclonal 1:250; 1 h RT
CD68 Dako Tris–HCl, 15 min MW Mouse Monoclonal 1:100; O/N 4 C
CD163 Leica Tris–HCl, 15 min MW Mouse Monoclonal 1:200; O/N 4 C
GFAP Dako None Rabbit Polyclonal 1:800; O/N 4 C
MW microwave; min minutes; O/N = overnight; h hour; RT room temperature
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antibody (ab#150533) concomitant either with anti-CD68,
anti-CD163 or anti-GFAP (Table 1). Followed by the re-
spective secondary antibodies labeled with either goat anti-
rabbit Alexa 647 (1:400,Invitrogen) or goat anti-mouse
Alexa 488 (Invitrogen). Nuclei were counterstained with
40-6 diamidino-2-phenylindole (DAPI, 1:25000, Sigma)
and sections mounted with Vectashield.
Statistical analysis
Statistical analyses were performed with IBM SPSS
statistics version 20. Statistical significance was set at
P\ 0.05. A non-parametric Wilcoxon Signed Ranks Test
was used to assess differences between ligand induced
migration and CHIPS inhibition.
Results
FPR1 is expressed in all GBM patient samples
Immunohistochemical analysis of GBM samples (FFPE)
showed that FPR1 has a relative diffuse cytoplasmic
staining in tumor cells. Blood vessels were negative for
FPR1 and served as a negative internal control. All 141
patient samples on TMA showed FPR1 expression. Semi-
quantitative evaluation of all core biopsies on TMA re-
sulted in an average intensity of 2 (Fig. 1a, b). Six samples
displayed 1 negative core and 2 samples contained 2
negative cores. In the remaining specimens all 4 cores
stained positive. In 3-control paraffin sections of pneumo-
nia patient samples, FPR1 was highly expressed on both
neutrophils and broncho-alveolar epithelial cells as previ-
ously described [15, 16] (Supplementary Fig. 1a). In
healthy brain tissue, neuron cell bodies were slightly FPR1
positive [17] (Supplementary Fig. 1b). Quantitative
evaluation of FPR1 in 37 frozen GBM sections resulted in
an average amongst all tumors of 33 ± 14 % of FPR1
positive cells (Fig. 1c, d). In the frozen sections FPR1
expression was stronger along the cell membranes than in
the cytoplasm.
FPR1 mRNA was detected in all 25 GBM patient
samples. Values varied from the lowest detectable mRNA
levels (2-DCT = 9.34 9 10-4) to the highest detectable
levels (2-DCT = 1.1 9 10-1) (Fig. 1e). These findings
indicate that FPR1 is highly expressed in human GBM.
The activation of U87 cells by mitochondrial
peptides can be inhibited with CHIPS
U87 cells stimulated with fMLKLIV and fMMYALF ex-
hibited a dose dependent calcium release up to 37 ± 15 %
(fMLKLIV) and 30 ± 49 % (fMMYALF) (Fig. 2a, c).
CHIPS treatment completely inhibited calcium release in-
duced by mitochondrial derived fMLKLIV and fMMYALF
(Fig. 2b, d; Table 2). These results show that mitochon-
drial peptides induce calcium mobilization in U87 cells,
which can be inhibited with CHIPS.
CHIPS inhibits mitochondrial peptide induced AKT
and ERK1/2 phosphorylation in U87
Stimulation of U87 cells for 5, 15 or 30 min with
fMLKLIV or fMMYALF, induced AKT(ser473) phos-
phorylation (Fig. 2e, f). Densitometric quantification
showed that at the same time points, CHIPS pre-treatment
inhibited respectively 46 ± 33, 52 ± 7 and 67 ± 12 % of
the fMLKLIV-induced phosphorylation (Supplementary
Fig. 2a). Similarly in cells stimulated with fMMYALF and
pre-treated with CHIPS, respectively 67 ± 39, 78 ± 29
and 70 ± 40 % of fMMYALF-induced AKT phosphory-
lation was inhibited (Supplementary Fig. 2b). Furthermore
fMLKLIV-induced phosporylation of ERK1/2 at 5, 15 and
30 min was completely inhibited with CHIPS (100 %) at
all three time points (Fig. 2g) (Supplementary Fig. 2c).
Moreover at 5, 15, and 30 min, fMMYALF-induced
ERK1/2 phosphorylation could be inhibited up to respec-
tively 94 ± 16, 99 ± 1 and 92 ± 12 % when treated with
CHIPS (Fig. 2h)(Supplementary Fig. 2d). This indicates
that mitochondrial peptide induced phosphorylation of
AKT and ERK1/2 in U87 cells can be potently inhibited
with CHIPS.
CHIPS inhibits U87 migration triggered
by fMLKLIV, fMMYALF and fMLF
U87 cells migrated towards the ligands fMLF, fMMYALF
and fMLKIV. When preincubating cells with 10 lg/mL
CHIPS, cell migration towards fMLF (control),
fMMYALF and fMLKLIV was inhibited up to 42 ± 14 %
(P = 0.018), 34 ± 27 % (P = 0.028) and 36 ± 29 %
(P = 0.028) respectively (Fig. 2i), indicating that migra-
tion of U87 cells towards mitochondrial peptides can be
inhibited with CHIPS.
FPR1 activation and mRNA expression could not be
detected in GG cell lines
None of the GG cell lines showed calcium mobilization
upon stimulation with fMLF (Supplementary Fig. 3). Ad-
ditionally FPR1 mRNA could not be detected in any of the
8 GG cell lines while the U87 positive control did exhibit
FPR1 mRNA (2-DCT = 2.3 9 10-3)(Supplementary
Fig. 2e). These results indicate that GG cell lines in vitro
retained no functional FPR1 and did not express FPR1
mRNA.2
56 J Neurooncol (2015) 123:53–63
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FPR1 is expressed on primary tumor tissue
from which GG cell lines were isolated
The discrepancy between FPR1 expression in GBM patient
samples (Fig. 1a–d) and its absence in GG cell lines
prompted us to evaluate the primary GBM patient material
from which these cells were isolated. Interestingly im-
munohistochemistry on the paired tumors from which the
GG cell lines were originally obtained, all exhibited FPR1



















































Fig. 1 Detection of FPR1 expression on Tissue Micro Array, frozen
sections and qPCR. Bar histogram representing results obtained from a
Tissue MicroArray (TMA). Immunohistochemical detection of FPR1
(ab#150533) expression on formalin fixed-paraffin embedded GBM
patient specimens. Semi-quantitative evaluation was performed by
averaging the scores of 4 cores derived from each patient specimen and
plotted with a corresponding bar. The intensity of FPR1 expression was
scored on a scale from 0 to 3; 0 being negative, 1 positive but with
focal and diffuse staining, 2 prevalently focal and more intense staining
and 3 exhibiting highly intense focal staining. On average patient
samples exhibited an intensity score of 2. All samples were positive for
FPR1 (a). Representative pictures of 4 different core biopsies
containing FPR1 intensities from 0 to 3 (b). Immunohistochemical
detection of FPR1 (ab#101659) expression on 36 frozen GBM patient
samples and quantification containing on average 32 ± 14 % FPR1
positive cells (c). Representative FPR1 immunohistochemical staining
on a frozen GBM section (d). FPR1 mRNA detection on GBM snap
frozen tissue samples by qPCR. All samples were loaded in 4
replicates, FPR1 mRNA values varied from minimum (2-DCT =
9.34 9 10-4) to maximum (2-DCT = 1.1 9 10-1) (e)



























































































































Fig. 2 Inhibition of mitochondrial induced FPR1 activity by CHIPS
in U87 cells. Mitochondrial peptides fMLKLIV and fMMYALF
induce dose dependent calcium mobilization (10-6 M–10-8 M) of
U87 cells (a, c), which can be dose dependently inhibited with
0.01–10 lg/mL CHIPS (b, d). In U87 cells 10-6 M fMLKLIV or
fMMYALF induced AKT phosphorylation on the Ser473 site at 5, 15
and 30 min. At the same time points 10 lg/mL CHIPS showed
46 ± 33, 52 ± 7, 67 ± 12 % inhibition of fMLKLIV induced
phosphorylation and respectively 67 ± 39, 78 ± 29, 70 ± 40 %
inhibition of fMMYALF-induced phosporylation (e, f). A concentra-
tion of 10-6 M fMLKLIV or fMMYALF induce ERK1/2
phosphorylation in U87 cells at 5, 15 and 30 min. When U87 cells
were pre-treated with CHIPS (10 lg/mL), fMLKLIV induced phos-
phorylation was inhibited up to 100 % and fMMYALF-induced
phosphorylation was inhibited 94 ± 16, 99 ± 1 and 92 ± 12 %
(respectively at time points 5, 15 and 30 min) (g and h). For migration
in transwell assays each time the cell migration towards one of the
ligands was set at 100 % and inhibition with CHIPS was plotted
against it. Migration towards fMLF, fMMYALF and fMLKLIV of
U87 cells was inhibited up to 42 ± 14 % (P = 0.018), 34 ± 27 %
(P = 0.028) and 36 ± 29 % (P = 0.028) when pretreated with
10 lg/mL CHIPS. Values are indicated as mean ± SD (i)
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In GBM tissue samples FPR1 is expressed on glial
tumor cells and on macrophages
FPR1 is primarily known for its expression on immune
cells [18]. To confirm the presence of FPR1 on tumor cells,
double immunofluorescence was performed on GBM pa-
tient samples. Results showed FPR1 co-expression with
GFAP (Fig. 3e), and also with CD68 and CD163 (Fig. 3f,
g). This indicates that FPR1 expression is present on tumor
cells as well as on macrophages.
FPR1 expression is present in orthotopic tumors
of early passage glioblastoma cells
The GG cell lines tested were FPR1 negative in vitro, while
the paired GBM tissues expressed FPR1 (Fig. 3a–d, Sup-
plementary Fig. 4). Therefore the tumor tissue obtained by
orthotopic implantation in the brain of GG cell lines in
NOD-SCID IL-2 c-knockout mice was evaluated. Tumors
were positive with variable intensities (Fig. 4e–h), while all
slides from FFPE blocks of cultured GG cell lines were
FPR1 negative (Fig. 4a–d). Negative controls are depicted
Supplementary Fig. 5. The human nature of the tumors was
confirmed with anti-human-nestin staining [12, 19]. These
findings suggest that GG cell lines lacking FPR1 in vitro,
form tumors with regained receptor expression when in-
tracranially implanted in NOD-SCID IL-2 c-knockout mice.
Discussion
Our findings show that the FPR1 protein is highly ex-
pressed in GBM and that its expression is stimulated by the
microenvironment. We detected FPR1 expression in a large
series of human GBM tumors and showed that the migra-
tion of U87 cells is activated by human mitochondrial
peptides. Mitochondrial peptide induced activity in U87
cells could be inhibited with CHIPS. FPR1 expression was
not detected in 8 early passage cell lines isolated from
primary GBM tissue, while their originating tumors did
express FPR1. When these cell lines were intracranially
injected in mice, the developed tumors regained FPR1
expression thus suggesting a role for the microenvironment
in fostering the expression of FPR1.
This is the first time that immunohistochemical FPR1
expression has been investigated in a large series of human
GBM tumors. FPR1 immunohistochemistry showed dif-
ferences in staining patterns for paraffin and frozen human
GBM sections. Specifically paraffin sections exhibited a
more diffuse cytoplasmic staining while the frozen sections
showed stronger membranous staining. This is likely due to
differences between the two antibodies used; one being
directed against the second extracellular loop and the other
directed against the internal region of FPR1. The only other
study investigating FPR1 in six GBM patient specimens
reported receptor expression in all GBM specimens as
detected by immunohistochemistry [6]. Overall our find-
ings of the universal expression of FPR1 in human GBM
tumors, together with previous reports on the contribution
of FPR1 to the survival benefit of animals treated with
siRNA against FPR1 [9, 20], indicate that this receptor
might be a interesting target for novel drug development.
GBMs are typically characterized by extensive areas of
necrosis. Previous findings showed that the supernatant of
necrotic U87 cells activated FPR1 as proven by calcium
mobilization and increased chemotaxis [6]. The effects of
the necrotic supernatant on FPR1 were probably, at least in
part, caused by the presence of free-floating mitochondrial
peptides. Mitochondrial peptide affinity and activity on
FPR1 was previously reported in transfected HL-60 cells
[21]. Together with bacterial peptide fMLF these are the
only source formylated peptides in nature and are charac-
terized by highly conserved patterns. This indicates that the
ruptured cells in the necrotic GBM microenvironment may
affect the broad number of FPR1 positive cells that are
present.
Table 2 Ligand induced calcium mobilization with CHIPS inhibition of U87 cells
Concentration Inhibition with CHIPS (%)
0 lg/mL
% stimulation
0.01 lg/mL 0.1 lg/mL 1 lg/mL 10 lg/mL
fMLKLIV
10-6 M 100 – – 100 ± 2 –
10-7 M 22 ± 43 3.0 ± 34 81 ± 8 105 ± 6 110 ± 15
10-8 M -4.3 ± 7.3 – – 100 ± 2 –
fMMYALF
10-6 M 100 30 ± 31 87 ± 41 114 ± 25 126 ± 6
10-7 M 30 ± 19 – – 97 ± 3.8 –
10-8M -5.0 ± 6 – – 98 ± 5.7 –




























Fig. 3 Immuno -hisotochemical and -fluorescence detection of FPR1
(ab#150533) alone or coupled with GFAP and CD68/CD163 markers.
Representative photomicrographs depicting immunohistochemical
expression of FPR1 in the GBM patient specimens and its derived
primary GBM cell line. The original patient specimens all displayed
FPR1 expression with variable intensities. Images of patient GBM
tissue of which GG cell lines were obtained (a–d). Immunofluores-
cence image displaying GFAP single expression (arrow) and co-
expression with FPR1 (arrow head) (panel e). FPR1 shows single
expression (asterisk) and co-expression with CD68 (arrow head)
(panel f). Single stained FPR1 cells (asterisk) and co-expression with
CD163 (arrow head) (panel g)
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We showed for the first time that mitochondrial peptides
directly affect the behavior of U87 cells. Activation of the
FPR1 expressing U87 GBM cell line by mitochondrial
peptides fMLKLIV and fMMYALF elicited calcium mo-
bilization, FPR1 downstream protein phosphorylation and
migration. All these responses could be inhibited with
CHIPS. Our results are in line with previous findings,
which showed a role for FPR1 in malignant tumor cell
activity. Namely, incubation of U87 with the bacterial
peptide fMLF stimulated cell migration [6], induced the
upregulation of HIF-1a [6] and VEGF [6, 9]. However the
use of mitochondrial peptides resembles more closely the
conditions of the tumor milieu. Moreover the ability of
CHIPS to inhibit all mitochondrial peptide induced re-
sponses on U87 cells makes it a potential drug for further
investigation.
To further study the effects of the microenvironment on
FPR1 we screened a number of early passage GBM cell
lines for FPR1 expression. Early passage GBM cell line
models are often used to bring new insights into the eti-
ology of GBM [25] and are generally considered to re-















Fig. 4 Immunohistochemical detection of FPR1 (ab#150533) ex-
pression in brain tissue sections of NOD-SCID IL-2 c-knockout mice
orthotopically injected with GG cell lines. Paraffin embedded samples
of the cell lines GG12, GG13, GG14 and GG16 were negative for
FPR1 (a–d). Mouse brain injected with GG12, GG13, GG14 and
GG16 cell lines all showed tumor formation. All tumors expressed
FPR1 with variable intensities (panels e–h). Arrow heads indicate the
FPR1 positively stained GG cells
J Neurooncol (2015) 123:53–63 61
123
cell lines [26]. The observation that none of the 8 tested
GG cell lines expressed FPR1 was quite unexpected, as all
the paired GBM samples did express FPR1. This discrep-
ancy could be the result of heterogeneous FPR1 expression
within the tumor or of FPR1 being mostly present on im-
mune cells. In original tumor material, with double im-
munofluorescence we confirmed that receptor expression
occurred in GFAP-positive astrocytic tumor cells as well as
on CD68/CD163-positive microglia/macrophages. Huang
and colleagues found no co-expression of FPR1 and GFAP,
which led them to conclude that FPR1 is associated with a
more undifferentiated cell state [27]. These experiments
were performed on U87 cells and thus in an in vitro setting.
The GG cell lines were cultured as neurospheres in serum
free media supplemented with EGF and FGF, favoring the
growth of undifferentiated, cancer stem-like cells [12].
However, we could not detect FPR1 in our early passage
GG cell lines. Next we showed that when implanted into
mouse brains, the GG cells lacking FPR1 expression
in vitro, exhibited the FPR1 membrane expression in vivo.
These results show that the GG cell lines still retain the
capacity to express FPR1 and suggest that the microenvi-
ronment influences the receptor expression of these cells.
Overall, FPR1 is highly expressed in GBMs and the
microenvironment plays an important role in modulating
FPR1 activation and expression.
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